BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jia Y, Wang H, Wang Y, Wang T, Wang M, Ma M, Duan Y, Meng X, Liu L. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 2015;137:1095-106. [PMID: 25683635 DOI: 10.1002/ijc.29481] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Lanser L, Kink P, Egger EM, Willenbacher W, Fuchs D, Weiss G, Kurz K. Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. Front Immunol 2020;11:249. [PMID: 32153576 DOI: 10.3389/fimmu.2020.00249] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
2 Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Ann Transl Med 2020;8:1095. [PMID: 33145314 DOI: 10.21037/atm-20-3735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol 2021;896:173921. [PMID: 33529725 DOI: 10.1016/j.ejphar.2021.173921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Davar D, Bahary N. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. Targ Oncol 2018;13:125-40. [DOI: 10.1007/s11523-017-0547-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
5 Vichaya EG, Vermeer DW, Budac D, Lee A, Grossberg A, Vermeer PD, Lee JH, Dantzer R. Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer. Int J Tryptophan Res 2019;12:1178646919872508. [PMID: 31496720 DOI: 10.1177/1178646919872508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Zhang T, Tan XL, Xu Y, Wang ZZ, Xiao CH, Liu R. Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer. Chin Med J (Engl) 2017;130:710-6. [PMID: 28303855 DOI: 10.4103/0366-6999.201613] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
7 Duan Y, Jia Y, Wang J, Liu T, Cheng Z, Sang M, Lv W, Qin J, Liu L. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1. Cell Death Dis 2021;12:587. [PMID: 34099633 DOI: 10.1038/s41419-021-03858-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wang J, Liu T, Wang M, Lv W, Wang Y, Jia Y, Zhang R, Liu L. SRSF1‐dependent alternative splicing attenuates BIN1 expression in non–small cell lung cancer. J Cell Biochem 2020;121:946-53. [DOI: 10.1002/jcb.29366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Meireson A, Devos M, Brochez L. IDO Expression in Cancer: Different Compartment, Different Functionality? Front Immunol 2020;11:531491. [PMID: 33072086 DOI: 10.3389/fimmu.2020.531491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
10 Pei Z, Mendonca R, Gazzard L, Pastor R, Goon L, Gustafson A, VanderPorten E, Hatzivassiliou G, Dement K, Cass R, Yuen PW, Zhang Y, Wu G, Lin X, Liu Y, Sellers BD. Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2). ACS Med Chem Lett 2018;9:417-21. [PMID: 29795752 DOI: 10.1021/acsmedchemlett.7b00427] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
11 Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC. Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget 2016;7:26670-9. [PMID: 27050369 DOI: 10.18632/oncotarget.8476] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhang Y, Sun Z, Mao X, Wu H, Luo F, Wu X, Zhou L, Qin J, Zhao L, Bai C. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. Oncotarget 2017;8:85526-36. [PMID: 29156738 DOI: 10.18632/oncotarget.20241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
13 Li Y, Liu J, Cai XW, Li HX, Cheng Y, Dong XH, Yu W, Fu XL. Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review. Crit Rev Oncol Hematol 2021;167:103466. [PMID: 34508841 DOI: 10.1016/j.critrevonc.2021.103466] [Reference Citation Analysis]
14 Ge Z, Wu S, Zhang Z, Ding S. Mechanism of tumor cells escaping from immune surveillance of NK cells. Immunopharmacol Immunotoxicol 2020;42:187-98. [PMID: 32223464 DOI: 10.1080/08923973.2020.1742733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Ferreira JM, Dellê H, Camacho CP, Almeida RJ, Reis ST, Matos YST, Lima AMR, Leite KRM, Pontes-Júnior J, Srougi M. Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer. Int Urol Nephrol 2020;52:1477-82. [PMID: 32152758 DOI: 10.1007/s11255-020-02414-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 2017;76:167-82. [PMID: 28324751 DOI: 10.1016/j.ejca.2017.01.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 158] [Article Influence: 32.4] [Reference Citation Analysis]
18 Kolios G. Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? Dig Dis Sci 2016;61:330-1. [PMID: 26694171 DOI: 10.1007/s10620-015-3997-x] [Reference Citation Analysis]
19 Luo B, Que ZJ, Zhou ZY, Wang Q, Dong CS, Jiang Y, Hu B, Shi H, Jin Y, Liu JW, Li HG, Wang L, Tian JH. Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model. J Integr Med 2018;16:283-9. [PMID: 29752140 DOI: 10.1016/j.joim.2018.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
20 Li W, Qie J, Zhang Y, Chang J. Spatiotemporal Changes in Checkpoint Molecule Expression. Adv Exp Med Biol 2020;1248:167-200. [PMID: 32185711 DOI: 10.1007/978-981-15-3266-5_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Zheng J, Wang J, Jia Y, Liu T, Duan Y, Liang X, Liu L. microRNA-211 promotes proliferation, migration, and invasion ability of oral squamous cell carcinoma cells via targeting the bridging integrator 1 protein. J Cell Biochem 2019;120:4644-53. [PMID: 30260023 DOI: 10.1002/jcb.27753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
22 Cui G, Li C, Xu G, Sun Z, Zhu L, Li Z, Zheng W, Li J, Yuan A. Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers. Pathol Oncol Res 2018;24:269-75. [PMID: 28470572 DOI: 10.1007/s12253-017-0244-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
23 Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Cancer Med 2020;9:8086-121. [PMID: 32875727 DOI: 10.1002/cam4.3410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
24 Acovic A, Gazdic M, Jovicic N, Harrell CR, Fellabaum C, Arsenijevic N, Volarevic V. Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract. Therap Adv Gastroenterol 2018;11:1756284818815334. [PMID: 30574192 DOI: 10.1177/1756284818815334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
25 Rubel F, Kern JS, Technau-Hafsi K, Uhrich S, Thoma K, Häcker G, von Bubnoff N, Meiss F, von Bubnoff D. Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival. J Invest Dermatol 2018;138:679-87. [PMID: 29054599 DOI: 10.1016/j.jid.2017.09.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
26 Su L, Guo W, Lou L, Nie S, Zhang Q, Liu Y, Chang Y, Zhang X, Li Y, Shen H. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Mol Carcinog 2020;59:520-32. [PMID: 32134157 DOI: 10.1002/mc.23176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
27 Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends Cancer 2018;4:38-58. [PMID: 29413421 DOI: 10.1016/j.trecan.2017.11.005] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 15.0] [Reference Citation Analysis]
28 Lee HH, Kang H, Cho H. Natural killer cells and tumor metastasis. Arch Pharm Res 2017;40:1037-49. [PMID: 28871566 DOI: 10.1007/s12272-017-0951-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
29 Zong S, Li C, Luo C, Zhao X, Liu C, Wang K, Jia W, Bai M, Yin M, Bao S, Guo J, Kang J, Duan T, Zhou Q. Dysregulated expression of IDO may cause unexplained recurrent spontaneous abortion through suppression of trophoblast cell proliferation and migration. Sci Rep 2016;6:19916. [PMID: 26814137 DOI: 10.1038/srep19916] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
30 Zhao L, Ma M, Wu H, Zhang C, Dai S, Dong P, Huo B, Shan B. p-Hydroxylcinnamaldehyde slows the progression of 4NQO-induced oesophageal tumourigenesis via the RhoA-MAPK signaling pathway. Mol Carcinog 2018;57:1319-31. [PMID: 29873419 DOI: 10.1002/mc.22847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Wu SG, Li FY, Chen Y, Sun JY, Lin HX, Lin Q, He ZY. Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis. J Cancer Res Clin Oncol 2017;143:467-74. [PMID: 27812853 DOI: 10.1007/s00432-016-2295-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Wang J, Jia Y, Zhao S, Zhang X, Wang X, Han X, Wang Y, Ma M, Shi J, Liu L. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene 2017;36:6235-43. [PMID: 28714960 DOI: 10.1038/onc.2017.217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
33 Wu SG, He ZY, Wang Y, Sun JY, Lin HX, Su GQ, Li Q. Lymph node dissection improved survival in patients with metastatic thoracic esophageal cancer: An analysis of 220 patients from the SEER database. Int J Surg 2016;35:13-8. [PMID: 27613123 DOI: 10.1016/j.ijsu.2016.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
34 Wang S, Wu J, Shen H, Wang J. The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis. BMC Cancer 2020;20:471. [PMID: 32456621 DOI: 10.1186/s12885-020-06956-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Barreto FS, Chaves Filho AJ, de Araújo MC, de Moraes MO, de Moraes ME, Maes M, de Lucena DF, Macedo DS. Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer. Behavioural Pharmacology 2018;29:165-80. [DOI: 10.1097/fbp.0000000000000384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
36 Wang Y, Hu GF, Wang ZH. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. Onco Targets Ther 2017;10:3557-66. [PMID: 28790848 DOI: 10.2147/OTT.S136259] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Li S, Han X, Lyu N, Xie Q, Deng H, Mu L, Pan T, Huang X, Wang X, Shi Y, Zhao M. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Sci 2018;109:3726-36. [PMID: 30264546 DOI: 10.1111/cas.13811] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
38 Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. Oncotarget 2018;9:23482-93. [PMID: 29805749 DOI: 10.18632/oncotarget.25235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
39 Qian S, Zhang M, Chen Q, He Y, Wang W, Wang Z. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. RSC Adv 2016;6:7575-81. [DOI: 10.1039/c5ra25046c] [Cited by in Crossref: 33] [Article Influence: 5.5] [Reference Citation Analysis]
40 Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. Int Rev Cell Mol Biol 2018;336:175-203. [PMID: 29413890 DOI: 10.1016/bs.ircmb.2017.07.004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 18.0] [Reference Citation Analysis]
41 Ma M, Zhang C, Xiang XH, Deng XQ, Dai SL, Wei SS, Zhang XM, Zhao LM, Liu YJ, Shan BE. p-Hydroxylcinnamaldehyde from cochinchinamomordica seed reverses resistance to TRAIL in human oesophageal squamous cell carcinoma via the activation of the p38 mitogen-activated protein kinase signalling pathway. Biomed Pharmacother 2020;121:109611. [PMID: 31731196 DOI: 10.1016/j.biopha.2019.109611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Yeung A, Terentis A, King N, Thomas S. Role of indoleamine 2,3-dioxygenase in health and disease. Clinical Science 2015;129:601-72. [DOI: 10.1042/cs20140392] [Cited by in Crossref: 122] [Cited by in F6Publishing: 69] [Article Influence: 17.4] [Reference Citation Analysis]
43 Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release 2018;289:125-45. [DOI: 10.1016/j.jconrel.2018.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
44 Liu XH, Zhai XY. Role of tryptophan metabolism in cancers and therapeutic implications. Biochimie 2021;182:131-9. [PMID: 33460767 DOI: 10.1016/j.biochi.2021.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zheng Y, Li Y, Lian J, Yang H, Li F, Zhao S, Qi Y, Zhang Y, Huang L. TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J Transl Med 2019;17:165. [PMID: 31109341 DOI: 10.1186/s12967-019-1917-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
46 Zhang T, Zhang Z, Li F, Ping Y, Qin G, Zhang C, Zhang Y. miR-143 Regulates Memory T Cell Differentiation by Reprogramming T Cell Metabolism. J Immunol 2018;201:2165-75. [PMID: 30150287 DOI: 10.4049/jimmunol.1800230] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
47 Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res 2017;23:6650-60. [PMID: 28751450 DOI: 10.1158/1078-0432.CCR-17-0120] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 15.8] [Reference Citation Analysis]
48 Jasek K, Kubatka P, Samec M, Liskova A, Smejkal K, Vybohova D, Bugos O, Biskupska-Bodova K, Bielik T, Zubor P, Danko J, Adamkov M, Kwon TK, Büsselberg D. DNA Methylation Status in Cancer Disease: Modulations by Plant-Derived Natural Compounds and Dietary Interventions. Biomolecules 2019;9:E289. [PMID: 31323834 DOI: 10.3390/biom9070289] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
49 Porcellato I, Brachelente C, Cappelli K, Menchetti L, Silvestri S, Sforna M, Mecocci S, Iussich S, Leonardi L, Mechelli L. FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors. Vet Pathol 2021;58:42-52. [PMID: 33021155 DOI: 10.1177/0300985820960131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Wang X, Wang J, Jia Y, Wang Y, Han X, Duan Y, Lv W, Ma M, Liu L. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition. Oncotarget 2017;8:19661-73. [PMID: 28152502 DOI: 10.18632/oncotarget.14914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
51 Lv W, Jia Y, Wang J, Duan Y, Wang X, Liu T, Hao S, Liu L. Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p. Cell Death Discov 2022;8:60. [PMID: 35149697 DOI: 10.1038/s41420-022-00825-9] [Reference Citation Analysis]
52 Huang H, Jiang C, Shen S, Liu A, Gan Y, Tong Q, Chen S, Gao Z, Du J, Cao J, Wang J. Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy. Nano Lett 2019;19:5356-65. [DOI: 10.1021/acs.nanolett.9b01807] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
53 Teoh ST, Lunt SY. Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond: Metabolism in cancer metastasis. WIREs Syst Biol Med 2018;10:e1406. [DOI: 10.1002/wsbm.1406] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
54 Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. J Immunol Res 2020;2020:2862647. [PMID: 33029538 DOI: 10.1155/2020/2862647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Perez-Castro L, Garcia R, Venkateswaran N, Barnes S, Conacci-Sorrell M. Tryptophan and its metabolites in normal physiology and cancer etiology. FEBS J 2021. [PMID: 34687129 DOI: 10.1111/febs.16245] [Reference Citation Analysis]
56 Zhang X, Wang J, Jia Y, Liu T, Wang M, Lv W, Zhang R, Shi J, Liu L. CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC. Cancer Cell Int 2019;19:226. [PMID: 31496920 DOI: 10.1186/s12935-019-0952-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
57 Ahmadzada T, Lee K, Clarke C, Cooper WA, Linton A, McCaughan B, Asher R, Clarke S, Reid G, Kao S. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer 2019;130:35-41. [PMID: 30885349 DOI: 10.1016/j.lungcan.2019.02.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
58 Zhang X, Xiong H, Duan J, Chen X, Liu Y, Huang C. The Prognostic Significance of the BIN1 and CCND2 Gene in Adult Patients with Acute Myeloid Leukemia. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01479-w] [Reference Citation Analysis]
59 Yentz S, Smith D. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs 2018;32:311-7. [PMID: 29980987 DOI: 10.1007/s40259-018-0291-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
60 Leja-Szpak A, Góralska M, Link-Lenczowski P, Czech U, Nawrot-Porąbka K, Bonior J, Jaworek J. The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1). Anticancer Agents Med Chem 2019;19:2079-90. [PMID: 30987575 DOI: 10.2174/1871520619666190415165212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Jia Y, Tian C, Wang H, Yu F, Lv W, Duan Y, Cheng Z, Wang X, Wang Y, Liu T, Wang J, Liu L. Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin. Mol Cancer 2021;20:162. [PMID: 34893064 DOI: 10.1186/s12943-021-01455-y] [Reference Citation Analysis]
62 Jia Y, Duan Y, Liu T, Wang X, Lv W, Wang M, Wang J, Liu L. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5. Cell Death Dis 2019;10:573. [PMID: 31363080 DOI: 10.1038/s41419-019-1811-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 62] [Article Influence: 17.3] [Reference Citation Analysis]